期刊
NUTRIENTS
卷 14, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/nu14153009
关键词
vitamin D; vitamin D insufficiency; secondary hyperparathyroidism; parathyroid hormone; chronic kidney disease; chronic kidney disease-mineral and bone disorder
资金
- Vifor Pharma Deutschland GmbH
This review examines the developments of vitamin D therapies in CKD patients and discusses the association between vitamin D deficiency and sHPT as well as its impact on important clinical outcomes in CKD patients. However, vitamin D therapy also comes with the risk of side effects, so it is necessary to address core issues regarding PTH target levels, optimal vitamin D levels, and the effectiveness of sHPT treatment in CKD patients.
The association between vitamin D deficiency and especially critical shortage of active vitamin D (1,25-dihydroxyvitamin D, calcitriol) with the development of secondary hyperparathyroidism (sHPT) is a well-known fact in patients with chronic kidney disease (CKD). The association between sHPT and important clinical outcomes, such as kidney disease progression, fractures, cardiovascular events, and mortality, has turned the prevention and the control of HPT into a core issue of patients with CKD and on dialysis. However, vitamin D therapy entails the risk of unwanted side effects, such as hypercalcemia and hyperphosphatemia. This review summarizes the developments of vitamin D therapies in CKD patients of the last decades, from calcitriol substitution to extended-release calcifediol. In view of the study situation for vitamin D insufficiency and sHPT in CKD patients, we conclude that the nephrology community has to solve three core issues: (1) What is the optimal parathyroid hormone (PTH) target level for CKD and dialysis patients? (2) What is the optimal vitamin D level to support optimal PTH titration? (3) How can sHPT treatment support reduction in the occurrence of hard renal and cardiovascular events in CKD and dialysis patients?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据